ArriVent BioPharma, Inc. is a US-based biopharmaceutical company focusing on developing targeted cancer therapies, particularly for non-small cell lung cancer. Their lead product, Furmonertinib, is a third-generation tyrosine kinase inhibitor undergoing multiple clinical trials.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing